| A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma (NCT05420324) | Eucure (Beijing) Biopharma Co., Ltd | 2022-06-13 |
| Axitinib and Nivolumab for the Treatment of Mucosal Melanoma (NCT05384496) | Memorial Sloan Kettering Cancer Center | 2022-05-17 |
| Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6 (NCT04830124) | Mural Oncology, Inc | 2021-09-27 |
| A Beta-only IL-2 ImmunoTherapY Study (NCT05086692) | Medicenna Therapeutics, Inc. | 2021-08-27 |
| Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM (NCT05009446) | Eye & ENT Hospital of Fudan University | 2021-08-10 |
| The Value of [18F]FDG PET/CT Imaging in Prognostic Evaluation of Mucosal Melanoma (NCT07506447) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2021-01-01 |
| Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma (NCT04622566) | Peking University Cancer Hospital & Institute | 2020-12-30 |
| A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas (NCT04551352) | Hoffmann-La Roche | 2020-10-28 |
| Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma (NCT04472806) | Fudan University | 2020-06-20 |
| Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study (NCT04462965) | Peking University Cancer Hospital & Institute | 2020-05-30 |
| Atypical MOLes and Melanoma Early Detection Study (MoleMed) (NCT04353050) | Russian Academy of Medical Sciences | 2020-04-01 |
| Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma (NCT04180995) | Peking University Cancer Hospital & Institute | 2019-08-06 |
| Apatinib Plus SHR1210 in Advanced Mucosal Melanoma (NCT03986515) | Henan Cancer Hospital | 2019-06-04 |
| A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma (NCT03698019) | National Cancer Institute (NCI) | 2019-02-15 |
| A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors (NCT03611868) | Ascentage Pharma Group Inc. | 2018-08-29 |
| Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma. (NCT03602547) | AnewPharma | 2018-07-31 |
| Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma (NCT03220009) | National Cancer Institute (NCI) | 2017-11-03 |
| Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma (NCT03033576) | National Cancer Institute (NCI) | 2017-10-23 |
| Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma (NCT03241186) | Robert R. McWilliams, MD | 2017-09-12 |
| Molecular Characterization of Primary Mucosal Melanoma (NCT03319693) | CHU de Reims | 2017-08-28 |
| A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab (NCT02978443) | Georgetown University | 2017-07-26 |
| The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery (NCT03178123) | Shanghai Junshi Bioscience Co., Ltd. | 2017-05-31 |
| Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases (NCT02858869) | Emory University | 2016-10-04 |
| Neoadjuvant and Adjuvant Checkpoint Blockade (NCT02519322) | M.D. Anderson Cancer Center | 2016-02-02 |
| Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists (NCT02126579) | Craig L Slingluff, Jr | 2014-05-01 |
| A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma (NCT02129075) | National Cancer Institute (NCI) | 2014-04-09 |
| Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery (NCT02158520) | Academic and Community Cancer Research United | 2013-10-18 |
| Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma (NCT01961115) | Fred Hutchinson Cancer Center | 2013-09-13 |
| Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV (NCT01166126) | National Cancer Institute (NCI) | 2010-10-01 |
| Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era (NCT03138642) | Sun Yat-sen University | 2010-07-01 |
| Dinaciclib in Treating Patients With Stage IV Melanoma (NCT00937937) | National Cancer Institute (NCI) | 2009-07-01 |
| Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma (NCT00424515) | Dana-Farber Cancer Institute | 2006-07-01 |
| Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (NCT00110019) | National Cancer Institute (NCI) | 2005-06-01 |
| Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma (NCT00085189) | University of Southern California | 2004-05-01 |
| Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery (NCT01989572) | National Cancer Institute (NCI) | 2000-02-23 |